Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation

White, Craig A.; Affeldt, J.C.

doi:10.1016/j.ajoc.2022.101584

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK therapy includes a diverse spectrum such as nerve growth factor (NGF) eye drops, neuropeptides (substance P), surgical therapy, and autologous blood-based eye drops ( 48 , 58 , 59 ). OXERVATE ® (cenegermin-bkbj), an FDA-approved topical recombinant human nerve growth factor, was reported as an efficient therapy in moderate to severe NK that can lead to significant improvement in corneal sensation and complete resolution of epithelial defect ( 60 – 62 ). Bandage contact lenses (BCLs) are another therapy option for NK patients that provide corneal epithelium protection; they are widely used in some conditions like exposure keratopathy, limbal stem cell deficiency (LSCD), and severe dryness ( 60 , 63 ).…”

Section: Discussionmentioning

confidence: 99%

“…OXERVATE ® (cenegermin-bkbj), an FDA-approved topical recombinant human nerve growth factor, was reported as an efficient therapy in moderate to severe NK that can lead to significant improvement in corneal sensation and complete resolution of epithelial defect ( 60 – 62 ). Bandage contact lenses (BCLs) are another therapy option for NK patients that provide corneal epithelium protection; they are widely used in some conditions like exposure keratopathy, limbal stem cell deficiency (LSCD), and severe dryness ( 60 , 63 ). Unfortunately, despite the curative effects of autologous serum and cord blood eye drops in modulating NK progress, they have toxic pro-inflammatory components that limit their usage ( 64 – 66 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Sabater

Ghalibafan

Osei

et al. 2023

Preprint

View full text Add to dashboard Cite

Background/Aims: Neurotrophic keratitis (NK) is a neurodegenerative disease that can lead to corneal hypoesthesia, decreased tear production, and epitheliopathy. Based on the severity of ocular surface damage, NK is classified into 3 stages. Stage 1 NK is characterized by superficial punctate keratopathy, tear film instability, and reduced corneal sensation. The therapeutic efficacy of PRGF eye drops for NK stages 2 and 3 has been previously reported. In this study, we evaluated the efficacy and safety of autologous PRGF eye drops in improving corneal sensitivity and other ocular surface clinical signs in patients with stage 1 NK. Methods: Retrospective chart review Results: 26 eyes of 15 stage 1 NK patients (seven males, eight females), aged 76.3 ± 12.1 years, were included in the study. The mean treatment duration was 2 ± 1.8 months. With PRGF treatment, corneal sensitivity increased from 2.8 to 4.5 cm in 53.8% (14/26) (p < 0.01), TBUT increased from 3.6 to 5.0 s in 69.2% (18/26) (p < 0.01), and Schirmer score increased from 13.7 to 16.8 mm in 80.7% (21/26) of treated eyes (p < 0.01). Similarly, an improvement in corneal staining (punctate epithelial erosions) and MMP-9 levels was seen in 80.7% (n = 21) and 65.4% (n = 17) of treated eyes, respectively. BCVA improvement was seen in 26.9% of treated eyes (n = 7). Conclusions:This study demonstrates the effective role of PRGF therapy in recovering corneal sensation and tear film function and in the healing of corneal erosions in stage 1 NK patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Sabater

Ghalibafan

Osei

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Escherichia coliin the production of biopharmaceuticals

İncir,

Kaplan

2024

Biotech and App Biochem

View full text Add to dashboard Cite

Escherichia colihas shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, inE. coliand its use in treating diabetes. After insulin, many biopharmaceuticals produced fromE. colihave been approved by the US Food and Drug Administration and the European Medicines Agency to treat various human diseases. AlthoughE. colihas some disadvantages, such as lack of post‐translational modifications and toxicity, it is an important host with advantages such as being a well‐known bacterium in recombinant protein production, cheap, simple production system, and high yield. This study examined biopharmaceuticals produced and approved inE. coliunder the headings of peptides, hormones, enzymes, fusion proteins, antibody fragments, vaccines, and other pharmaceuticals. The topics on which these biopharmaceuticals were approved for treating human diseases, when and by which company they were produced, and their use and development in the field are included.

show abstract

Cenegermin/ciprofloxacin/moxifloxacin

2022

Reactions Weekly

View full text Add to dashboard Cite

Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation

Cited by 4 publications

References 20 publications

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Escherichia coliin the production of biopharmaceuticals

Cenegermin/ciprofloxacin/moxifloxacin

Contact Info

Product

Resources

About